NEW YORK – January 25, 2025 (NEWMEDIAWIRE) – Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Applied Therapeutics (NASDAQ:), Inc. (Applied Therapeutics or the Company) (NASDAQ: APLT) on behalf of investors who purchased or otherwise acquired securities of Applied Therapeutics between January 3, 2024 and December 2, 2024 (the appeal).
CLICK HERE TO JOIN THE CASE
If you are an investor in Applied Therapeutics and have suffered losses, you can CLICK HERE to contact us. You can also contact Kaplan Fox by email at jcampisi@kaplanfox.com or by calling (212) 329-8571.
DEADLINE REMINDER: If you are a member of the proposed class, you may petition the court no later than February 18, 2025 to serve as lead plaintiff of the proposed class. If you experience losses, we encourage you to contact us to learn more about the lead plaintiff process. You do not need to seek to become a lead plaintiff in order to participate in a potential recovery.
According to the complaint, on November 27, 2024, the company disclosed that the United States Food and Drug Administration (FDA) had issued a complete response letter (CRL) for its new drug application for govorestat, AT-007- 1002, for the treatment of classic diseases. galactosemia (the NDA). The company’s press release states that the CRLs indicate[d] that the FDA has completed its review of the application and determined that it is unable to approve the NDA in its current form, citing deficiencies in clinical application.
Following this news, on November 29, 2024, Applied Therapeutics’ stock fell $6.54 per share, or more than 76%, to close at $2.03 per share due to heavy trading volume. important.
Then, on December 2, 2024, after the markets closed, the Company disclosed in a Form 8-K that following the issuance of the CRL, the Company had received a warning letter limited to review AT-007-1002 and that the warning letter identified issues with electronic data capture and a dosing error in the dose escalation phase of the study, resulting in levels slightly lower than targeted in a number limited number of patients, a problem which was corrected before reaching the maintenance dosage. According to the complaint, Applied Therapeutics’ stock price fell from a closing price of $1.75 per share on December 2, 2024 to $1.29 per share on December 5, 2024.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm specializing in complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With more than 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record its clients demand. By litigating at the federal and state levels, Kaplan Fox has successfully shaped the law, winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you can visit our website at www.kaplanfox.com.
This press release may be considered attorney advertising in some jurisdictions under applicable law and ethical rules.
If you have any questions regarding this Notice, your rights or interests, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th floor
New York, New York 10022
(212) 329-8571
jcampisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999, rue Harrison, suite 1560
Oakland, CA 94612
(415) 772-4704
lking@kaplanfox.com
View the original version at www.newmediawire.com
Copyright 2025 JCN Newswire. All rights reserved.
